Penn spinout REGENXBIO, co-founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, announced positive results from a phase II study for its treatment ABBV-RGX-314. This treatment is designed as a one-time gene therapy for wet age-related macular degeneration (wet AMD), an eye disease that causes blurred or distorted vision.
In a study evaluating the effectiveness of ABBV-RGX-314 in patients with bilateral wet AMD, the nine patients who received a single dose of ABBV-RGX-314 using subretinal delivery saw a 97% reduction during the following 9 months in anti-VEGF eye injections, their previous method of treatment. Read more here.